Search

Your search keyword '"Yang, Guorong"' showing total 156 results
Start Over Author "Yang, Guorong"
156 results on '"Yang, Guorong"'

8. Leukocyte Telomere Length and the Risk of Prostate Cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study.

Author

Lv, Kaikai, Wu, Yangyang, Yang, Guorong, Hao, Xiaowei, Huang, Shuai, Song, Tao, and Yuan, Qing

Subjects
BENIGN prostatic hyperplasia, DISEASE risk factors, PROSTATE cancer, TELOMERES, LEUCOCYTES
Abstract

Background Previous observational studies have been controversial regarding the association of leukocyte telomere length (LTL) with prostate cancer (PCa) and benign prostatic hyperplasia (BPH). Methods First, we conducted an observational study utilizing UK Biobank data. The correlation between LTL and the risk of PCa and BPH was evaluated via multivariate-adjusted logistic regression. Then, we conducted a 2-sample Mendelian randomization to examine causal links between LTL (472 174 individuals) and PCa as well as BPH. To verify the reliability of the primary analysis, we conducted a second analysis and sensitivity analyses. Results In the UK Biobank study, individuals in the longer quartiles of LTL were observed to have a higher risk of PCa (1.155-fold to 1.349-fold, all p  < .001) and BPH (1.119-fold to 1.212-fold, all p  < .001) compared to those in the lowest quartile in multivariate-adjusted logistic regression. We observed that genetically predicted longer LTL resulted in a 1.427-fold risk of PCa (odds ratio [OR] = 1.427, 95% confidence interval [CI] = 1.197–1.702, p  < .001) and 1.539-fold risk of BPH (OR = 1.539, 95% CI = 1.387–1.707, p  < .001) in the primary analysis. In the second analysis, the results also indicated that longer LTL increased the genetic liability to both PCa (OR = 1.338, 95% CI = 1.189–1.507, p  < .001) and BPH (OR = 1.006, 95% CI = 1.003–1.008, p  < .001). Sensitivity analyses also supported the reliability of the results. Conclusions Our study provides convincing evidence supporting that longer LTL increases the risk of PCa and BPH in European individuals. Large-scale studies are needed to elucidate the potential mechanisms of LTL in PCa and BPH occurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Author

Beltran, Pedro, Calzone, Frank, Mitchell, Petia, Chung, Young-Ah, Cajulis, Elaina, Moody, Gordon, Belmontes, Brian, Li, Chi-Ming, Vonderfecht, Steven, Velculescu, Victor, Yang, Guorong, Qi, Jingwei, Slamon, Dennis, and Konecny, Gottfried

Subjects
Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Blotting, Western, Carboplatin, Cell Line, Tumor, Cell Proliferation, Cisplatin, Drug Synergism, Female, Flow Cytometry, Humans, Insulin-Like Growth Factor II, Mice, Mice, Nude, Ovarian Neoplasms, PTEN Phosphohydrolase, Paclitaxel, Receptor, IGF Type 1, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, Transcriptome, Xenograft Model Antitumor Assays
Abstract

PURPOSE: Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal antibody against IGF-IR. Here, we explore the therapeutic potential of ganitumab for the treatment of ovarian cancer. EXPERIMENTAL DESIGN: The effects of ganitumab were tested in vitro against a panel of 23 established ovarian cancer cell lines. The ability of ganitumab to inhibit IGF-I-, IGF-II-, and insulin-mediated signaling was examined in vitro and in tumor xenografts using ovarian cancer models displaying IGF-IR/PI3K/AKT pathway activation by two distinct mechanisms, PTEN loss and IGF-II overexpression. Drug interactions between ganitumab and cisplatin, carboplatin, or paclitaxel were studied in vitro and in vivo. RESULTS: In vitro, growth inhibition varied significantly among individual ovarian cancer cell lines. IGF-II mRNA and phospho-IGF-IR protein expression were quantitatively correlated with response to ganitumab, and PTEN mutations conferred resistance to ganitumab. Ganitumab potently inhibited baseline and IGF-I-, IGF-II-, and insulin-induced IGF-IR and IGF-IR/insulin hybrid receptor signaling in vitro and in vivo. Synergistic and additive drug interactions were seen for ganitumab and carboplatin or paclitaxel in vitro. Furthermore, ganitumab significantly increased the efficacy of cisplatin in ovarian cancer xenograft models in vivo. CONCLUSIONS: These observations provide a biologic rationale to test ganitumab as a single agent or in combination with carboplatin/cisplatin and paclitaxel in patients with ovarian cancer. Moreover, assessment of tumor expression of IGF-II, phospho-IGF-IR, or PTEN status may help select patients with ovarian cancer who are most likely to benefit from ganitumab. Clin Cancer Res; 20(11); 2947-58. ©2014 AACR.

Published
2014

13. Supplementary Figure 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Author

Beltran, Pedro J., primary, Calzone, Frank J., primary, Mitchell, Petia, primary, Chung, Young-Ah, primary, Cajulis, Elaina, primary, Moody, Gordon, primary, Belmontes, Brian, primary, Li, Chi-Ming, primary, Vonderfecht, Steven, primary, Velculescu, Victor E., primary, Yang, Guorong, primary, Qi, Jingwei, primary, Slamon, Dennis J., primary, and Konecny, Gottfried E., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 3 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Author

Beltran, Pedro J., primary, Calzone, Frank J., primary, Mitchell, Petia, primary, Chung, Young-Ah, primary, Cajulis, Elaina, primary, Moody, Gordon, primary, Belmontes, Brian, primary, Li, Chi-Ming, primary, Vonderfecht, Steven, primary, Velculescu, Victor E., primary, Yang, Guorong, primary, Qi, Jingwei, primary, Slamon, Dennis J., primary, and Konecny, Gottfried E., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure Legend from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Author

Beltran, Pedro J., primary, Calzone, Frank J., primary, Mitchell, Petia, primary, Chung, Young-Ah, primary, Cajulis, Elaina, primary, Moody, Gordon, primary, Belmontes, Brian, primary, Li, Chi-Ming, primary, Vonderfecht, Steven, primary, Velculescu, Victor E., primary, Yang, Guorong, primary, Qi, Jingwei, primary, Slamon, Dennis J., primary, and Konecny, Gottfried E., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Author

Beltran, Pedro J., primary, Calzone, Frank J., primary, Mitchell, Petia, primary, Chung, Young-Ah, primary, Cajulis, Elaina, primary, Moody, Gordon, primary, Belmontes, Brian, primary, Li, Chi-Ming, primary, Vonderfecht, Steven, primary, Velculescu, Victor E., primary, Yang, Guorong, primary, Qi, Jingwei, primary, Slamon, Dennis J., primary, and Konecny, Gottfried E., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Data from Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Author

Konecny, Gottfried E., primary, Winterhoff, Boris, primary, Kolarova, Teodora, primary, Qi, Jingwei, primary, Manivong, Kanthinh, primary, Dering, Judy, primary, Yang, Guorong, primary, Chalukya, Meenal, primary, Wang, He-Jing, primary, Anderson, Lee, primary, Kalli, Kimberly R., primary, Finn, Richard S., primary, Ginther, Charles, primary, Jones, Siân, primary, Velculescu, Victor E., primary, Riehle, Darren, primary, Cliby, William A., primary, Randolph, Sophia, primary, Koehler, Maria, primary, Hartmann, Lynn C., primary, and Slamon, Dennis J., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 2 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Author

Beltran, Pedro J., primary, Calzone, Frank J., primary, Mitchell, Petia, primary, Chung, Young-Ah, primary, Cajulis, Elaina, primary, Moody, Gordon, primary, Belmontes, Brian, primary, Li, Chi-Ming, primary, Vonderfecht, Steven, primary, Velculescu, Victor E., primary, Yang, Guorong, primary, Qi, Jingwei, primary, Slamon, Dennis J., primary, and Konecny, Gottfried E., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table S2 from Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Author

Konecny, Gottfried E., primary, Winterhoff, Boris, primary, Kolarova, Teodora, primary, Qi, Jingwei, primary, Manivong, Kanthinh, primary, Dering, Judy, primary, Yang, Guorong, primary, Chalukya, Meenal, primary, Wang, He-Jing, primary, Anderson, Lee, primary, Kalli, Kimberly R., primary, Finn, Richard S., primary, Ginther, Charles, primary, Jones, Siân, primary, Velculescu, Victor E., primary, Riehle, Darren, primary, Cliby, William A., primary, Randolph, Sophia, primary, Koehler, Maria, primary, Hartmann, Lynn C., primary, and Slamon, Dennis J., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 4 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Author

Beltran, Pedro J., primary, Calzone, Frank J., primary, Mitchell, Petia, primary, Chung, Young-Ah, primary, Cajulis, Elaina, primary, Moody, Gordon, primary, Belmontes, Brian, primary, Li, Chi-Ming, primary, Vonderfecht, Steven, primary, Velculescu, Victor E., primary, Yang, Guorong, primary, Qi, Jingwei, primary, Slamon, Dennis J., primary, and Konecny, Gottfried E., primary

Published
2023
Full Text
View/download PDF

21. Data from Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Author

Konecny, Gottfried E., primary, Winterhoff, Boris, primary, Kolarova, Teodora, primary, Qi, Jingwei, primary, Manivong, Kanthinh, primary, Dering, Judy, primary, Yang, Guorong, primary, Chalukya, Meenal, primary, Wang, He-Jing, primary, Anderson, Lee, primary, Kalli, Kimberly R., primary, Finn, Richard S., primary, Ginther, Charles, primary, Jones, Siân, primary, Velculescu, Victor E., primary, Riehle, Darren, primary, Cliby, William A., primary, Randolph, Sophia, primary, Koehler, Maria, primary, Hartmann, Lynn C., primary, and Slamon, Dennis J., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 5 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Author

Beltran, Pedro J., primary, Calzone, Frank J., primary, Mitchell, Petia, primary, Chung, Young-Ah, primary, Cajulis, Elaina, primary, Moody, Gordon, primary, Belmontes, Brian, primary, Li, Chi-Ming, primary, Vonderfecht, Steven, primary, Velculescu, Victor E., primary, Yang, Guorong, primary, Qi, Jingwei, primary, Slamon, Dennis J., primary, and Konecny, Gottfried E., primary

Published
2023
Full Text
View/download PDF

43. The relation of microsatellite instability to expression of hTERT in human gastric carcinoma

Author

Wan, Shunmei, Wan, Furong, Wan, Pingxin, Wan, Jianxin, He, Xiaoxia, Liu, Fuxia, and Yang, Guorong

Subjects
Original Article, neoplasms, digestive system diseases
Abstract

Objective: To investigate the role of microsatellite instability (MSI) in the pathogenesis of gastric carcinoma and its relationship with the expression of hTERT gene. Methods: 75 cases of gastric carcinoma and paired normal control tissues were included in this study. MSI of BAT-25, BAT-26, D5S346, D17S250 and D2S1235 were detected by PCR, native polyacrylamide gel electrophoresis, and silver staining while the expression of hTERT was localized by immunohistochemistry at the same time. Results: MSI positive rates of BAT-25, BAT-26, D5S346, D17S250 and D2S123 were 14.7%, 12.00%, 26.67%, 16% and 21.3%. MSI was obviously related with lymph node metastasis and pathologic stages respectively (P0.05). hTERT was not expressed in normal gastric mucosa, but in intestinal metaplasia, dysplasia, and gastric carcinoma. The positive rate of hTERT was 76% (57/75) in 75 cases of gastric carcinoma tissues. The expression of hTERT was obviously related to histological type (P0.05). The positive rate was higher in poorly differentiated cases than in moderately and well differentiated cases (P

Published
2019

45. Philosophical Horizons : Metaphysical Investigation in Chinese Philosophy

Author

Yang Guorong, Paul D'Ambrosio, Yang Guorong, and Paul D'Ambrosio

Subjects
Philosophy, Chinese--History, Metaphysics, Philosophy, Comparative
Abstract

Professor Yang Guorong is one of the foremost living philosophers in China, and is widely known for the development of his “concrete metaphysics.” In Philosophical Horizons Yang offers penetrating discussions of some of the most important issues in modern philosophy—especially those topics related to comparative and Chinese philosophy. Drawing freely and adroitly on Confucian, Daoist, and Buddhist texts, while staging a dialogue with Western thinkers such as from Kant and Hegel to Marx, Heidegger, and Wittgenstein, Yang shows how contemporary Chinese philosophy has adopted, localized, and critically developed Western ideas alongside traditional Chinese concepts.

Published
2019

46. Metaphysics

Author

Yang Guorong

Subjects
Philosophy, Optics, business.industry, Metaphysics, business, Reflection (computer graphics)
Published
2012

47. Morality and Human Existence

Author

Yang Guorong

Subjects
Philosophy, Moral development, media_common.quotation_subject, Perspective (graphical), Moral psychology, Metaphysics, Sociology, Social science, Morality, media_common, Moral disengagement, Epistemology
Published
2012

48. The Maturation of the Self and the Refinement of Things

Author

Yang Guorong

Subjects
Cognitive science, Philosophy, Self, Psychology
Abstract

(2012). The Maturation of the Self and the Refinement of Things. Contemporary Chinese Thought: Vol. 43, No. 4, pp. 51-85.

Published
2012

50. Feng Qi on Wisdom

Author

Yang Guorong and Huang Yong

Subjects
Philosophy, Work (electrical), Subject (philosophy), Modern philosophy, Classics
Abstract

Feng Qi (1915-1995) explored many areas of Chinese and Western, ancient and modern philosophy, but he was always most concerned with the idea of wisdom. The selections translated here are examples of his earliest (1944) and last (1994) work on this subject.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results